A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors - Trial NCT06235983
Access comprehensive clinical trial information for NCT06235983 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 1
Feb 29, 2024
Apr 30, 2027
Primary Outcome
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3537982,PK: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3537982
Summary
This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in
 Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this
 study is to determine how much of LY3537982 gets into the bloodstream and how long it takes
 the body to eliminate it in Chinese participants. The safety, tolerability and preliminary
 efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in
 this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06235983
Non-Device Trial